Business context and reporting period
This is TapImmune Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015. The request metadata names Marker Therapeutics, Inc.; the filing itself identifies the registrant as TapImmune Inc., so the entity match should be verified. TapImmune describes itself as a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious disease. It reported no revenue in either comparable quarter.
Financial results and liquidity
| Metric | Q1 2015 / March 31, 2015 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None in Q1 2014 |
| Operating expenses | $1.028 million | $1.187 million in Q1 2014 |
| Research and development | $609,378 | $22,500 in Q1 2014 |
| General and administrative | $418,786 | $1.164 million in Q1 2014 |
| Net loss | $981,724; $0.04 per share | $29.707 million; $3.89 per share in Q1 2014 |
| Cash and cash equivalents | $1.454 million | $141,944 at December 31, 2014 |
| Working capital | Deficit of $1.766 million | Deficit of $1.024 million at December 31, 2014 |
| Operating cash flow | Used $1.014 million | Used $372,954 in Q1 2014 |
| Financing cash flow | Provided $2.326 million | Provided $418,000 in Q1 2014 |
At March 31, current liabilities were $3.302 million, including a $2.053 million warrant derivative liability, $703,323 in accounts payable and accrued liabilities, $492,365 in research agreement obligations, and $52,942 in promissory notes. The filing reports no fixed repayment terms or interest on the promissory notes. Total assets were $1.536 million. The filing does not provide a clear gross-margin or operating-margin measure; with no revenue, these are not meaningful for the period.
Material changes and unusual items
- Net loss fell substantially from Q1 2014, which included a $27.663 million loss on debt extinguishment, $483,636 of convertible-note discount accretion, and other financing-related items. The year-over-year loss comparison therefore reflects unusual prior-period expenses, not revenue growth.
- G&A declined mainly because Q1 2015 had no comparable non-cash consulting stock compensation of approximately $686,000 recorded in Q1 2014. R&D increased as the company exercised an option to acquire Mayo Clinic technology and increased in-house research activity.
- January and March private placements issued approximately 12.32 million common shares. The cash flow statement reports $2.326 million of net share-issuance proceeds. The placements also issued substantial warrant coverage; 62.09 million warrants were issued in the quarter, and total warrants outstanding reached 64.74 million at quarter-end.
- The warrant derivative liability rose from $9,000 at year-end to $2.053 million, principally due to $2.090 million of additions, partly offset by a $46,000 fair-value gain. Its valuation depends on significant assumptions and could differ materially from eventual settlement amounts.
Outlook, risks, and contingencies
Management estimated spending of approximately $7.5 million over the next 12 months, assuming one Phase II clinical trial, and said significant additional financing is required. It stated that existing capital resources were insufficient to support operations and that financing may not be available on favorable terms, or at all. The filing expressly says these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Management planned to advance HER2/neu and Folate Receptor Alpha programs toward Phase II in 2015, continue Polystart technology development, and pursue additional financing and potential grant funding. These are forward-looking plans, not assured outcomes. The filing reports interim clinical observations, including immune responses in the studied patients, but these do not establish clinical efficacy or regulatory approval. Development, clinical-trial, financing, regulatory, and commercialization risks remain significant.
For legal matters, the company was seeking to collect a $196,204 arbitration award plus 9% interest from a consultant. A supplier had obtained a $51,000 judgment, which the company said it intended to settle in Q2 2015; the amount was accrued. Management also concluded that disclosure controls and procedures were not effective as of quarter-end. No material changes to internal control over financial reporting were reported during the quarter.
Key facts for investors to verify
- Confirm that this TapImmune filing, rather than a Marker Therapeutics filing, is the intended company and period.
- Assess the going-concern warning against the $1.454 million cash balance, $1.766 million working-capital deficit, operating cash burn, and stated $7.5 million funding need.
- Review the financing terms, warrant reset features, potential dilution, and the valuation of the $2.053 million warrant liability.
- Verify subsequent clinical-trial progress, Mayo Clinic licensing status, and whether planned Phase II programs and financing were achieved.
- Follow the collection of the arbitration award, settlement of the supplier judgment, and remediation of ineffective disclosure controls.